Analyst firms · Mizuho · BIIB
Mizuho BIIB price target and rating history
Biogen Inc. (BIIB) · Health Care
Mizuho rates Biogen Inc. (BIIB) Buy with a $270 price target, as of its latest action on Sep 28, 2022. It has published 3 rating actions on BIIB since October 2021, including 1 upgrade and 0 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.
- Current rating
- Buy
- Price target
- $270
- Median target, all firms
- $231.50
- Actions on BIIB
- 3
Mizuho price target on BIIB
Every Mizuho rating on BIIB
- Sep 28, 2022
- Jan 12, 2022
- Oct 26, 2021
How other firms rate BIIB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Buy | $280 | Oct 29, 2026 |
| Wolfe Research | Outperform | $300 | Aug 13, 2026 |
| Truist Securities | Buy | $235 | Jul 13, 2026 |
| Needham | Buy | $255 | Jun 8, 2026 |
| Evercore ISI | Outperform | May 15, 2026 | |
| UBS | Buy | $225 | Apr 22, 2026 |
| Wells Fargo | Overweight | $250 | Apr 20, 2026 |
| Piper Sandler | Overweight | $214 | Apr 14, 2026 |
| Barclays | Equal Weight | $185 | Feb 20, 2026 |
| H.C. Wainwright | Buy | $228 | Feb 9, 2026 |
| HSBC | Reduce | $143 | Dec 10, 2025 |
Questions about Mizuho and BIIB
- What is Mizuho's price target for BIIB?
- Mizuho's latest stated price target for Biogen Inc. (BIIB) is $270, from its action on Sep 28, 2022.
- What is Mizuho's rating on BIIB?
- Mizuho rates BIIB Buy, a bullish rating, as of Sep 28, 2022.
- When did Mizuho last change its view on BIIB?
- On Sep 28, 2022, Mizuho upgrades to Buy from Neutral, price target $207 to $270.
- How does Mizuho's BIIB target compare with other analysts?
- Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.
More BIIB rating histories
- Argus Research3
- Wolfe Research3
- Needham9
- UBS5
- Wells Fargo5
- Piper Sandler4
- Barclays4
- HSBC3
- Stifel5
- Jefferies3
- BMO Capital Markets4
- BofA Securities3
- Morgan Stanley8
- Raymond James3
- Robert W. Baird3
- RBC Capital Markets7
- Oppenheimer3
All Mizuho ratingsBIIB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.